Research Paper Volume 16, Issue 7 pp 6537—6549

Figure 4. Constructing and evaluating a nomogram by integrating the RS and clinicopathological features. (A–D) Construction and validation of the TRG-RS in patients with HCC in (A) training set; (B) entire TCGA cohort; (C) TCGA testing cohort; (D) GEO cohort using the KM survival curves. (E) Nomogram predicting the 1-, 3- and 5-year patient’s OS. The points identified on the point scale of each variable are totaled. Finally, beneath the total points, the probability of 1-, 3- or 5-year survival is projected on the scales below. (F) CC shows the actually observed and nomogram-predicted 1-, 3- and 5-year OS of patients. (G) The ROC curve shows the AUC value of the nomogram, the RS, and clinicopathologic features for predicting the patient’s survival. (H) Evaluating the clinical benefit of the nomogram and the RS using DCA. None indicates that all samples were negative and untreated; therefore, the net benefit is zero. All indicates that all samples were positive and treated. The x-axis shows the threshold probability. (I) TRG-RS comparison of clinical information of patients with HCC in TCGA-LIHC.